Exane Derivatives Avadel Pharmaceuticals PLC Put Options Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding AVDL
# of Institutions
6Shares Held
738KCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$5.39 Million3.88% of portfolio
-
Schulhoff & CO Inc137KShares$1.23 Million0.67% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$4,4950.0% of portfolio
-
American Research & Management Co.100Shares$8990.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$80.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $545M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...